Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Abbott announces first enrollments in TactiFlex PAF IDE study » 09:01
08/04/20
08/04
09:01
08/04/20
09:01
ABT

Abbott

$100.73 /

+0.05 (+0.05%)

Abbott announced first…

Abbott announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from paroxysmal atrial fibrillation, a type of irregular heartbeat. The study will evaluate the performance of the investigational TactiFlex Ablation Catheter, Sensor Enabled for people whose atrial fibrillation symptoms are unable to be managed by medication. The TactiFlex PAF IDE study will enroll 355 patients at multiple sites worldwide. Patients enrolled in the trial will receive an ablation procedure using Abbott's TactiFlex Ablation Catheter, SE. Data collected from the study will be submitted to support global regulatory approvals.

ShowHide Related Items >><<
ABT Abbott
$100.73 /

+0.05 (+0.05%)

ABT Abbott
$100.73 /

+0.05 (+0.05%)

07/31/20 Guggenheim
Guggenheim upgrades Tandem Diabetes to Buy, says tailwinds not fully baked in
07/23/20 Argus
Abbott price target raised to $125 from $110 at Argus
07/17/20 B. Riley FBR
B. Riley FBR starts ClearPoint at Buy, sees potential takeover
07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
ABT Abbott
$100.73 /

+0.05 (+0.05%)

ABT Abbott
$100.73 /

+0.05 (+0.05%)

ABT Abbott
$100.73 /

+0.05 (+0.05%)

ABT Abbott
$100.73 /

+0.05 (+0.05%)

On The Fly
Fly Intel: Alphabet downgrade among today's top calls on Wall Street » 09:53
07/31/20
07/31
09:53
07/31/20
09:53
TWOU

2U

$47.77 /

+3.88 (+8.84%)

, DRRX

Durect

$2.02 /

+0.08 (+4.12%)

, ABT

Abbott

$101.10 /

-0.45 (-0.44%)

, UNH

UnitedHealth

$302.23 /

-2.94 (-0.96%)

, TNDM

TNDM

/

+

, BABA

Alibaba

$252.66 /

-0.085 (-0.03%)

, FB

Facebook

$252.33 /

+17.7 (+7.54%)

, AMZN

Amazon.com

$3,194.03 /

+143.06 (+4.69%)

, GOOG

Alphabet

$1,470.54 /

-64.04 (-4.17%)

Check out today's top…

Open Full Text

ShowHide Related Items >><<
UNH UnitedHealth
$302.23 /

-2.94 (-0.96%)

TWOU 2U
$47.77 /

+3.88 (+8.84%)

TNDM TNDM
/

+

GOOG Alphabet
$1,470.54 /

-64.04 (-4.17%)

FB Facebook
$252.33 /

+17.7 (+7.54%)

DRRX Durect
$2.02 /

+0.08 (+4.12%)

BABA Alibaba
$252.66 /

-0.085 (-0.03%)

AMZN Amazon.com
$3,194.03 /

+143.06 (+4.69%)

ABT Abbott
$101.10 /

-0.45 (-0.44%)

TWOU 2U
$47.77 /

+3.88 (+8.84%)

07/31/20 Barrington
2U price target raised to $55 from $50 at Barrington
07/31/20 Credit Suisse
2U upgraded to Outperform from Neutral at Credit Suisse
07/31/20 Credit Suisse
2U upgraded to Outperform from Neutral at Credit Suisse
07/28/20 Piper Sandler
2U price target raised to $49 from $42 at Piper Sandler
DRRX Durect
$2.02 /

+0.08 (+4.12%)

07/30/20 Oppenheimer
Durect initiated with an Outperform at Oppenheimer
07/01/20 H.C. Wainwright
Durect alcoholic hepatitis efficacy could be seen in COVID, says H.C. Wainwright
06/29/20 B. Riley FBR
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
ABT Abbott
$101.10 /

-0.45 (-0.44%)

07/31/20 Guggenheim
Guggenheim upgrades Tandem Diabetes to Buy, says tailwinds not fully baked in
07/23/20 Argus
Abbott price target raised to $125 from $110 at Argus
07/17/20 B. Riley FBR
B. Riley FBR starts ClearPoint at Buy, sees potential takeover
07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
UNH UnitedHealth
$302.23 /

-2.94 (-0.96%)

07/16/20 SVB Leerink
UnitedHealth price target raised to $370 from $360 at SVB Leerink
07/16/20 Oppenheimer
UnitedHealth price target raised to $353 from $343 at Oppenheimer
07/16/20 Deutsche Bank
UnitedHealth price target raised to $312 from $293 at Deutsche Bank
TNDM TNDM
/

+

07/31/20 Craig-Hallum
Tandem Diabetes price target raised to $140 from $102 at Craig-Hallum
07/31/20 Lake Street
Tandem Diabetes price target raised to $137 from $125 at Lake Street
07/31/20 Guggenheim
Tandem Diabetes upgraded to Buy from Neutral at Guggenheim
BABA Alibaba
$252.66 /

-0.085 (-0.03%)

07/31/20 Stifel
Stifel downgrades Alphabet to Hold, prefers other mega cap tech stocks
07/20/20
Alibaba initiated with a Buy at CMB International
07/17/20 Baird
Alibaba price target raised to $275 from $230 at Baird
07/17/20 Stifel
Alibaba price target raised to $270 from $230 at Stifel
FB Facebook
$252.33 /

+17.7 (+7.54%)

07/31/20
Facebook price target raised to $300 from $290 at JPMorgan
07/31/20 Wedbush
Facebook price target raised to $300 from $250 at Wedbush
07/31/20 RBC Capital
Facebook price target raised to $320 from $271 at RBC Capital
07/31/20 Raymond James
Facebook price target raised to $280 from $240 at Raymond James
AMZN Amazon.com
$3,194.03 /

+143.06 (+4.69%)

07/31/20 BMO Capital
Amazon.com price target raised to $3,700 from $3,500 at BMO Capital
07/31/20 RBC Capital
Amazon.com price target raised to $3,800 from $3,300 at RBC Capital
07/31/20 Guggenheim
Amazon.com price target raised to $3,600 from $2,700 at Guggenheim
07/31/20 Goldman Sachs
Amazon.com price target raised to $4,200 from $3,800 at Goldman Sachs
GOOG Alphabet
$1,470.54 /

-64.04 (-4.17%)

07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 Guggenheim
Alphabet price target raised to $1,725 from $1,580 at Guggenheim
07/31/20 Raymond James
Alphabet price target raised to $1,700 from $1,425 at Raymond James
07/31/20 Oppenheimer
Alphabet price target raised to $1,685 from $1,445 at Oppenheimer
UNH UnitedHealth
$302.23 /

-2.94 (-0.96%)

TWOU 2U
$47.77 /

+3.88 (+8.84%)

TNDM TNDM
/

+

GOOG Alphabet
$1,470.54 /

-64.04 (-4.17%)

FB Facebook
$252.33 /

+17.7 (+7.54%)

DRRX Durect
$2.02 /

+0.08 (+4.12%)

BABA Alibaba
$252.66 /

-0.085 (-0.03%)

AMZN Amazon.com
$3,194.03 /

+143.06 (+4.69%)

ABT Abbott
$101.10 /

-0.45 (-0.44%)

UNH UnitedHealth
$302.23 /

-2.94 (-0.96%)

TWOU 2U
$47.77 /

+3.88 (+8.84%)

GOOG Alphabet
$1,470.54 /

-64.04 (-4.17%)

FB Facebook
$252.33 /

+17.7 (+7.54%)

BABA Alibaba
$252.66 /

-0.085 (-0.03%)

AMZN Amazon.com
$3,194.03 /

+143.06 (+4.69%)

ABT Abbott
$101.10 /

-0.45 (-0.44%)

UNH UnitedHealth
$302.23 /

-2.94 (-0.96%)

TWOU 2U
$47.77 /

+3.88 (+8.84%)

TNDM TNDM
/

+

GOOG Alphabet
$1,470.54 /

-64.04 (-4.17%)

FB Facebook
$252.33 /

+17.7 (+7.54%)

DRRX Durect
$2.02 /

+0.08 (+4.12%)

BABA Alibaba
$252.66 /

-0.085 (-0.03%)

ABT Abbott
$101.10 /

-0.45 (-0.44%)

UNH UnitedHealth
$302.23 /

-2.94 (-0.96%)

TWOU 2U
$47.77 /

+3.88 (+8.84%)

GOOG Alphabet
$1,470.54 /

-64.04 (-4.17%)

FB Facebook
$252.33 /

+17.7 (+7.54%)

DRRX Durect
$2.02 /

+0.08 (+4.12%)

BABA Alibaba
$252.66 /

-0.085 (-0.03%)

AMZN Amazon.com
$3,194.03 /

+143.06 (+4.69%)

ABT Abbott
$101.10 /

-0.45 (-0.44%)

GOOG Alphabet
$1,470.54 /

-64.04 (-4.17%)

AMZN Amazon.com
$3,194.03 /

+143.06 (+4.69%)

Upgrade
Guggenheim upgrades Tandem Diabetes to Buy, says tailwinds not fully baked in » 07:50
07/31/20
07/31
07:50
07/31/20
07:50
TNDM

TNDM

/

+

, UNH

UnitedHealth

$305.17 /

-1.41 (-0.46%)

, ABT

Abbott

$101.55 /

-1 (-0.98%)

As previously reported,…

As previously reported, Guggenheim analyst Chris Pasquale upgraded Tandem Diabetes (TNDM) to Buy from Neutral with a $130 price target after the company reported "robust" Control-IQ adoption and better than expected new patient adds as it saw far less COVID-related disruption than he thought it might back in April. While shares have already re-rated, Pasquale does not think the stock has baked in the "growing list of tailwinds" he sees over the next 12-18 months, including a full year with access to UnitedHealth's (UNH) T1D members, international roll outs and his "sense" that integration with Abbot's (ABT) Libre could come by the second half of 2021.

ShowHide Related Items >><<
UNH UnitedHealth
$305.17 /

-1.41 (-0.46%)

TNDM TNDM
/

+

ABT Abbott
$101.55 /

-1 (-0.98%)

TNDM TNDM
/

+

07/31/20 Guggenheim
Tandem Diabetes upgraded to Buy from Neutral at Guggenheim
07/31/20 Piper Sandler
Tandem Diabetes price target raised to $125 from $90 at Piper Sandler
07/09/20 Piper Sandler
Tandem, Medtronic deal meant to mitigate litigation risk, says Piper Sandler
07/07/20 Cowen
Tandem Diabetes price target raised to $110 from $85 at Cowen
UNH UnitedHealth
$305.17 /

-1.41 (-0.46%)

07/16/20 SVB Leerink
UnitedHealth price target raised to $370 from $360 at SVB Leerink
07/16/20 Oppenheimer
UnitedHealth price target raised to $353 from $343 at Oppenheimer
07/16/20 Deutsche Bank
UnitedHealth price target raised to $312 from $293 at Deutsche Bank
07/16/20 Credit Suisse
UnitedHealth price target raised to $335 from $325 at Credit Suisse
ABT Abbott
$101.55 /

-1 (-0.98%)

07/23/20 Argus
Abbott price target raised to $125 from $110 at Argus
07/17/20 B. Riley FBR
B. Riley FBR starts ClearPoint at Buy, sees potential takeover
07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
07/14/20 Morgan Stanley
Edwards' removal of patent overhang a positive, says Morgan Stanley
UNH UnitedHealth
$305.17 /

-1.41 (-0.46%)

TNDM TNDM
/

+

ABT Abbott
$101.55 /

-1 (-0.98%)

UNH UnitedHealth
$305.17 /

-1.41 (-0.46%)

ABT Abbott
$101.55 /

-1 (-0.98%)

UNH UnitedHealth
$305.17 /

-1.41 (-0.46%)

TNDM TNDM
/

+

ABT Abbott
$101.55 /

-1 (-0.98%)

UNH UnitedHealth
$305.17 /

-1.41 (-0.46%)

ABT Abbott
$101.55 /

-1 (-0.98%)

Hot Stocks
Abbott receives FDA approval for Patient Controller app » 09:02
07/23/20
07/23
09:02
07/23/20
09:02
AAPL

Apple

$389.22 /

+1.19 (+0.31%)

, ABT

Abbott

$100.16 /

+1.98 (+2.02%)

Abbott (ABT) announced it…

Abbott (ABT) announced it has received approval from the U.S. FDA for the use of the company's Patient Controller app on compatible personal Apple (AAPL) smartphone devices. At Abbott, this approval allows patients living with neurological conditions, including chronic pain or movement disorders, the ability to manage therapy directly from their personal smartphone. With this app approval, the need to carry a separate patient programmer device is eliminated, streamlining the patient's experience and seamlessly integrating therapy management into their life. This is an important step in the integration and connection of digital health tools that ultimately help patients live fuller, healthier lives.

ShowHide Related Items >><<
ABT Abbott
$100.16 /

+1.98 (+2.02%)

AAPL Apple
$389.22 /

+1.19 (+0.31%)

AAPL Apple
$389.22 /

+1.19 (+0.31%)

07/23/20 Craig-Hallum
STMicroelectronics price target raised to $36 from $30 at Craig-Hallum
07/23/20 Goldman Sachs
Goldman calls recent Apple rally 'unsustainable,' says avoid shares
07/22/20 Morgan Stanley
Apple favorably set up for Q3 beat, says Morgan Stanley
07/16/20 Guggenheim
Best Buy price target raised to $100 from $90 at Guggenheim
ABT Abbott
$100.16 /

+1.98 (+2.02%)

07/23/20 Argus
Abbott price target raised to $125 from $110 at Argus
07/17/20 B. Riley FBR
B. Riley FBR starts ClearPoint at Buy, sees potential takeover
07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
07/14/20 Morgan Stanley
Edwards' removal of patent overhang a positive, says Morgan Stanley
ABT Abbott
$100.16 /

+1.98 (+2.02%)

AAPL Apple
$389.22 /

+1.19 (+0.31%)

ABT Abbott
$100.16 /

+1.98 (+2.02%)

AAPL Apple
$389.22 /

+1.19 (+0.31%)

ABT Abbott
$100.16 /

+1.98 (+2.02%)

AAPL Apple
$389.22 /

+1.19 (+0.31%)

ABT Abbott
$100.16 /

+1.98 (+2.02%)

AAPL Apple
$389.22 /

+1.19 (+0.31%)

AAPL Apple
$389.22 /

+1.19 (+0.31%)

Recommendations
Abbott price target raised to $125 from $110 at Argus » 08:03
07/23/20
07/23
08:03
07/23/20
08:03
ABT

Abbott

$100.16 /

+1.98 (+2.02%)

Argus analyst David Toung…

Argus analyst David Toung raised the firm's price target on Abbott to $125 from $110 and keeps a Buy rating on the shares. The analyst sees solid long-term growth prospects for Abbott as it introduces new products and invests in product development and market expansion. The analyst lowered the firm's full-year adjusted EPS estimate to $3.30 from $3.57, but raised the firm's 2021 estimate to $4.10 from $4.00.

ShowHide Related Items >><<
ABT Abbott
$100.16 /

+1.98 (+2.02%)

ABT Abbott
$100.16 /

+1.98 (+2.02%)

07/17/20 B. Riley FBR
B. Riley FBR starts ClearPoint at Buy, sees potential takeover
07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
07/14/20 Morgan Stanley
Edwards' removal of patent overhang a positive, says Morgan Stanley
07/13/20 Piper Sandler
Edwards Lifesciences patent settlement removes overhang, says Piper Sandler
ABT Abbott
$100.16 /

+1.98 (+2.02%)

ABT Abbott
$100.16 /

+1.98 (+2.02%)

ABT Abbott
$100.16 /

+1.98 (+2.02%)

ABT Abbott
$100.16 /

+1.98 (+2.02%)

Initiation
B. Riley FBR starts ClearPoint at Buy, sees potential takeover » 09:09
07/17/20
07/17
09:09
07/17/20
09:09
CLPT

ClearPoint Neuro

$3.80 /

+0.38 (+11.11%)

, MDT

Medtronic

$95.74 /

-1.42 (-1.46%)

, ABT

Abbott

$96.34 /

-0.4 (-0.41%)

B. Riley FBR analyst…

B. Riley FBR analyst Andrew D'Silva initiated coverage of ClearPoint Neuro (CLPT) with a Buy rating and $8 price target. The company is a leading provider of intra-procedural magnetic resonance imaging guided devices for the treatment and biopsy of intracranial neurological conditions, D'Silva tells investors in a research note. He believes a "best-in-class" technology, favorable industry backdrop, positive data, and "substantial momentum" indicate ClearPoint is reaching an inflection point, which will likely result in strong growth, a meaningful increase to gross margins, and share price appreciation. Further, ClearPoint Neuro could be an attractive acquisition target by larger players in the space, such as Medtronic (MDT) and Abbott (ABT), that may look to potentially limit market share erosion by integrating the company's disruptive" MRI-guided solutions, says D'Silva.

ShowHide Related Items >><<
MDT Medtronic
$95.74 /

-1.42 (-1.46%)

CLPT ClearPoint Neuro
$3.80 /

+0.38 (+11.11%)

ABT Abbott
$96.34 /

-0.4 (-0.41%)

CLPT ClearPoint Neuro
$3.80 /

+0.38 (+11.11%)

07/17/20 B. Riley FBR
ClearPoint Neuro initiated with a Buy at B. Riley FBR
03/12/20 Brookline
ClearPoint Neuro initiated with a Buy at Brookline
MDT Medtronic
$95.74 /

-1.42 (-1.46%)

07/16/20 Goldman Sachs
J&J delay to robotic surgery program a positive for Intuitive, says Goldman
07/09/20 Piper Sandler
Tandem, Medtronic deal meant to mitigate litigation risk, says Piper Sandler
06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
ABT Abbott
$96.34 /

-0.4 (-0.41%)

07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
07/14/20 Morgan Stanley
Edwards' removal of patent overhang a positive, says Morgan Stanley
07/13/20 Piper Sandler
Edwards Lifesciences patent settlement removes overhang, says Piper Sandler
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
MDT Medtronic
$95.74 /

-1.42 (-1.46%)

CLPT ClearPoint Neuro
$3.80 /

+0.38 (+11.11%)

ABT Abbott
$96.34 /

-0.4 (-0.41%)

MDT Medtronic
$95.74 /

-1.42 (-1.46%)

ABT Abbott
$96.34 /

-0.4 (-0.41%)

MDT Medtronic
$95.74 /

-1.42 (-1.46%)

ABT Abbott
$96.34 /

-0.4 (-0.41%)

MDT Medtronic
$95.74 /

-1.42 (-1.46%)

ABT Abbott
$96.34 /

-0.4 (-0.41%)

Hot Stocks
Abbott has sold 40M tests for COVID-19, management says » 09:42
07/16/20
07/16
09:42
07/16/20
09:42
ABT

Abbott

$96.74 /

+ (+0.00%)

The need for testing is…

The need for testing is "large and it isn't going away," the company said on its Q2 earnings conference call.

ShowHide Related Items >><<
ABT Abbott
$96.74 /

+ (+0.00%)

ABT Abbott
$96.74 /

+ (+0.00%)

07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
07/14/20 Morgan Stanley
Edwards' removal of patent overhang a positive, says Morgan Stanley
07/13/20 Piper Sandler
Edwards Lifesciences patent settlement removes overhang, says Piper Sandler
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
ABT Abbott
$96.74 /

+ (+0.00%)

ABT Abbott
$96.74 /

+ (+0.00%)

ABT Abbott
$96.74 /

+ (+0.00%)

ABT Abbott
$96.74 /

+ (+0.00%)

Options
Unusually active option classes on open July 16th » 09:40
07/16/20
07/16
09:40
07/16/20
09:40
NBRV

Nabriva Therapeutics

$0.66 /

+ (+0.00%)

, DPZ

Domino's Pizza

$415.58 /

+ (+0.00%)

, XLP

Consumer Staples Sector SPDR

$61.11 /

+ (+0.00%)

, AZN

AstraZeneca

$57.98 /

+ (+0.00%)

, MS

Morgan Stanley

$51.38 /

+ (+0.00%)

, ASHR

X-trackers Harvest CSI 300

$34.60 /

+ (+0.00%)

, KMI

Kinder Morgan

$14.97 /

+ (+0.00%)

, JNJ

Johnson & Johnson

$148.32 /

+ (+0.00%)

, STM

STMicroelectronics

$29.33 /

+ (+0.00%)

, ABT

Abbott

$96.74 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Nabriva Therapeutics (NBRV), Dominos (DPZ), Consumer Staples Sector SPDR ETF (XLP), AstraZeneca (AZN), Morgan Stanley (MS), db X trackers China (ASHR), Kinder Morgan (KMI), Johnson & Johnson (JNJ), STMicroelectronics (STM), and Abbott (ABT).

ShowHide Related Items >><<
STM STMicroelectronics
$29.33 /

+ (+0.00%)

NBRV Nabriva Therapeutics
$0.66 /

+ (+0.00%)

MS Morgan Stanley
$51.38 /

+ (+0.00%)

KMI Kinder Morgan
$14.97 /

+ (+0.00%)

JNJ Johnson & Johnson
$148.32 /

+ (+0.00%)

DPZ Domino's Pizza
$415.58 /

+ (+0.00%)

AZN AstraZeneca
$57.98 /

+ (+0.00%)

ABT Abbott
$96.74 /

+ (+0.00%)

NBRV Nabriva Therapeutics
$0.66 /

+ (+0.00%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
DPZ Domino's Pizza
$415.58 /

+ (+0.00%)

07/13/20 Wells Fargo
Domino's Pizza price target raised to $385 from $336 at Wells Fargo
07/13/20 RBC Capital
Domino's Pizza price target raised to $435 from $415 at RBC Capital
07/13/20 BTIG
Domino's Pizza price target raised to $440 from $405 at BTIG
07/10/20 MKM Partners
Domino's Pizza price target raised to $375 from $350 at MKM Partners
XLP Consumer Staples Sector SPDR
$61.11 /

+ (+0.00%)

10/23/19 Morgan Stanley
Procter & Gamble results could bode well for Walmart, says Morgan Stanley
AZN AstraZeneca
$57.98 /

+ (+0.00%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
MS Morgan Stanley
$51.38 /

+ (+0.00%)

07/08/20 Seaport Global
Morgan Stanley initiated with a Buy at Seaport Global
06/24/20
Fly Intel: Top five analyst upgrades
06/24/20 DA Davidson
Morgan Stanley upgraded to Buy from Neutral at DA Davidson
06/24/20 DA Davidson
Morgan Stanley upgraded to Buy from Neutral at DA Davidson
ASHR X-trackers Harvest CSI 300
$34.60 /

+ (+0.00%)

KMI Kinder Morgan
$14.97 /

+ (+0.00%)

07/07/20
Fly Intel: Top five analyst downgrades
07/06/20 Goldman Sachs
Kinder Morgan downgraded to Sell from Neutral at Goldman Sachs
05/18/20 BofA
Plains All American, GP Holdings cut to Underperform at BofA
04/07/20 Mizuho
Kinder Morgan price target lowered to $20 from $23 at Mizuho
JNJ Johnson & Johnson
$148.32 /

+ (+0.00%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
STM STMicroelectronics
$29.33 /

+ (+0.00%)

07/14/20 Cowen
STMicroelectronics price target raised to $34 from $30 at Cowen
07/14/20 Cowen
STMicroelectronics price target raised to $34 from $30 at Cowen
07/02/20 Credit Suisse
STMicroelectronics price target raised to EUR 28 at Credit Suisse
06/29/20 Bryan Garnier
STMicroelectronics upgraded to Buy from Neutral at Bryan Garnier
ABT Abbott
$96.74 /

+ (+0.00%)

07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
07/14/20 Morgan Stanley
Edwards' removal of patent overhang a positive, says Morgan Stanley
07/13/20 Piper Sandler
Edwards Lifesciences patent settlement removes overhang, says Piper Sandler
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
STM STMicroelectronics
$29.33 /

+ (+0.00%)

NBRV Nabriva Therapeutics
$0.66 /

+ (+0.00%)

MS Morgan Stanley
$51.38 /

+ (+0.00%)

KMI Kinder Morgan
$14.97 /

+ (+0.00%)

JNJ Johnson & Johnson
$148.32 /

+ (+0.00%)

DPZ Domino's Pizza
$415.58 /

+ (+0.00%)

AZN AstraZeneca
$57.98 /

+ (+0.00%)

ABT Abbott
$96.74 /

+ (+0.00%)

STM STMicroelectronics
$29.33 /

+ (+0.00%)

MS Morgan Stanley
$51.38 /

+ (+0.00%)

KMI Kinder Morgan
$14.97 /

+ (+0.00%)

JNJ Johnson & Johnson
$148.32 /

+ (+0.00%)

DPZ Domino's Pizza
$415.58 /

+ (+0.00%)

AZN AstraZeneca
$57.98 /

+ (+0.00%)

ABT Abbott
$96.74 /

+ (+0.00%)

STM STMicroelectronics
$29.33 /

+ (+0.00%)

NBRV Nabriva Therapeutics
$0.66 /

+ (+0.00%)

MS Morgan Stanley
$51.38 /

+ (+0.00%)

KMI Kinder Morgan
$14.97 /

+ (+0.00%)

JNJ Johnson & Johnson
$148.32 /

+ (+0.00%)

DPZ Domino's Pizza
$415.58 /

+ (+0.00%)

AZN AstraZeneca
$57.98 /

+ (+0.00%)

ABT Abbott
$96.74 /

+ (+0.00%)

STM STMicroelectronics
$29.33 /

+ (+0.00%)

NBRV Nabriva Therapeutics
$0.66 /

+ (+0.00%)

MS Morgan Stanley
$51.38 /

+ (+0.00%)

KMI Kinder Morgan
$14.97 /

+ (+0.00%)

JNJ Johnson & Johnson
$148.32 /

+ (+0.00%)

AZN AstraZeneca
$57.98 /

+ (+0.00%)

ASHR X-trackers Harvest CSI 300
$34.60 /

+ (+0.00%)

ABT Abbott
$96.74 /

+ (+0.00%)

XLP Consumer Staples Sector SPDR
$61.11 /

+ (+0.00%)

On The Fly
Fly Intel: Pre-market Movers » 09:05
07/16/20
07/16
09:05
07/16/20
09:05
ACIU

AC Immune

$7.20 /

+0.07 (+0.98%)

, LCI

Lannett

$5.16 /

+0.265 (+5.41%)

, DELL

Dell Technologies

$52.64 /

+0.2 (+0.38%)

, PAG

Penske Automotive

$44.69 /

+2.39 (+5.65%)

, ABT

Abbott

$96.74 /

+1.91 (+2.01%)

, BAC

Bank of America

$24.62 /

+0.485 (+2.01%)

, TWTR

Twitter

$35.68 /

+1.28 (+3.72%)

, TCDA

Tricida

$26.20 /

+0.42 (+1.63%)

, DIS

Disney

$120.91 /

+2.21 (+1.86%)

, APTO

Aptose Biosciences

$6.26 /

+0.61 (+10.80%)

, VMW

VMware

$139.57 /

+1.47 (+1.06%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

TCDA Tricida
$26.20 /

+0.42 (+1.63%)

PAG Penske Automotive
$44.69 /

+2.39 (+5.65%)

LCI Lannett
$5.16 /

+0.265 (+5.41%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

ACIU AC Immune
$7.20 /

+0.07 (+0.98%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

ACIU AC Immune
$7.20 /

+0.07 (+0.98%)

12/10/19 H.C. Wainwright
AC Immune price target raised to $11 from $8 at H.C. Wainwright
LCI Lannett
$5.16 /

+0.265 (+5.41%)

07/10/20 Raymond James
Raymond James lowers Lannett forecasts on fluphenazine competition
09/18/19 Truist
Lannett price target raised to $14 from $10 at SunTrust
08/29/19 Truist
Lannett price target raised to $10 from $7 at SunTrust
DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

07/16/20 Morgan Stanley
Morgan Stanley upgrades Dell Technologies on increasing odds of VMware spinoff
07/16/20 Morgan Stanley
Dell Technologies upgraded to Overweight from Equal Weight at Morgan Stanley
07/09/20
Fly Intel: Top five analyst initiations
07/09/20 Daiwa
Dell Technologies initiated with a Neutral at Daiwa
PAG Penske Automotive
$44.69 /

+2.39 (+5.65%)

07/08/20 JPMorgan
Penske Automotive price target raised to $43 from $39 at JPMorgan
06/23/20 Benchmark
Benchmark upgrades Penske Automotive to Buy with shares seen at discount
06/23/20 Benchmark
Penske Automotive upgraded to Buy from Hold at Benchmark
06/10/20 Truist
Penske Automotive price target raised to $48 from $42 at SunTrust
ABT Abbott
$96.74 /

+1.91 (+2.01%)

07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
07/14/20 Morgan Stanley
Edwards' removal of patent overhang a positive, says Morgan Stanley
07/13/20 Piper Sandler
Edwards Lifesciences patent settlement removes overhang, says Piper Sandler
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
BAC Bank of America
$24.62 /

+0.485 (+2.01%)

07/09/20 DA Davidson
Bank of America downgraded to Neutral from Buy at DA Davidson
07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Seaport Global
Bank of America initiated with a Neutral at Seaport Global
07/07/20 Societe Generale
Societe Generale upgrades BofA, Citi to Buy on 'path to respectability'
TWTR Twitter
$35.68 /

+1.28 (+3.72%)

07/15/20 MKM Partners
MKM Partners raises price targets on social media stocks
07/15/20 JPMorgan
Twitter price target raised to $33 from $29 at JPMorgan
07/14/20 Wedbush
Twitter sequential audience growth could surprise positively, says Wedbush
07/10/20 Morgan Stanley
Morgan Stanley says Twitter subscription would need to be $50/year for breakeven
TCDA Tricida
$26.20 /

+0.42 (+1.63%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

07/16/20 Cowen
Disney downgraded to Market Perform from Outperform at Cowen
07/13/20
Fly Intel: Top five analyst initiations
07/13/20 Goldman Sachs
Disney initiated with a Buy at Goldman Sachs
07/10/20 JPMorgan
JPMorgan has 'increasing conviction' in Disney returning to health
APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

06/12/20 Piper Sandler
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler
06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
VMW VMware
$139.57 /

+1.47 (+1.06%)

07/07/20 Deutsche Bank
Dell offers 20%-30% upside on standalone basis, says Deutsche Bank
06/24/20 Bernstein
Potential spinoff would be largely positive for VMware, says Bernstein
06/24/20
Fly Intel: Top five analyst upgrades
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

TCDA Tricida
$26.20 /

+0.42 (+1.63%)

PAG Penske Automotive
$44.69 /

+2.39 (+5.65%)

LCI Lannett
$5.16 /

+0.265 (+5.41%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

ACIU AC Immune
$7.20 /

+0.07 (+0.98%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

  • 16
    Jul
  • 17
    Dec
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

PAG Penske Automotive
$44.69 /

+2.39 (+5.65%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

ACIU AC Immune
$7.20 /

+0.07 (+0.98%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

Hot Stocks
Abbott reports Q2 FreeStyle Libre growth of 36.8% on reported basis » 07:35
07/16/20
07/16
07:35
07/16/20
07:35
ABT

Abbott

$96.74 /

+1.91 (+2.01%)

In Diabetes Care, strong…

In Diabetes Care, strong growth was led by FreeStyle Libre, which grew 36.8% on a reported basis and 39.9% on an organic basis versus the prior year. In June, Abbott announced U.S. FDA approval of FreeStyle Libre 2 as an integrated continuous glucose monitoring system for adults and children ages 4 and older with diabetes, achieving the highest level of accuracy and performance standards. The FreeStyle Libre 2 system will be available in the coming weeks at participating pharmacies and durable medical equipment providers at the same price as the currently available FreeStyle Libre 14 day system.

ShowHide Related Items >><<
ABT Abbott
$96.74 /

+1.91 (+2.01%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
07/14/20 Morgan Stanley
Edwards' removal of patent overhang a positive, says Morgan Stanley
07/13/20 Piper Sandler
Edwards Lifesciences patent settlement removes overhang, says Piper Sandler
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
ABT Abbott
$96.74 /

+1.91 (+2.01%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.